




PHARMACY AND POISONS BOARD

NEWSLETTER

www.ppb.go.ke



**Kenya Launches Strategy
to Accelerate Local HPT
Manufacturing**

→ Story Page 9



REPUBLIC OF KENYA

PHARMACY AND POISONS BOARD



MEDICINE SAFETY

STARTS WITH RESPONSIBLE USE




➔ **Avoid self-medication
and misuse of medicines.**

➔ **Consult your pharmacist.**



Ensuring quality, safe and efficacious health products and technologies in Kenya



Editorial Board

Editorial Advisor

Dr. Anthony Toroitch

Editor

Judy Sirima

Contributors

Judy Sirima

Naomi Naanyu

About The Newsletter

The PPB Newsletter is a publication of the Corporate Communication Division. It is designed to act as a tool of communication, documenting and disseminating important news and information to staff and stakeholders of the Board

Contacts

Corporate Communication Division,
Pharmacy and Poisons Board,
Lenana Road
P.O. Box 27663-00506 Nairobi.
Tel: +254-709-770-100
Email: pr@ppb.go.ke
info@ppb.go.ke
Web: web.pharmacyboardkenya.org

Design and Layout

Commwide Concepts

Email: commwideconcepts@gmail.com

Editor's Note

Welcome to Issue 34 of the PPB Newsletter, bringing you key updates on the Board's regulatory activities, stakeholder engagements and initiatives to strengthen the quality, safety and efficacy of health products and technologies.

We invite you to explore the latest developments and insights from the across the Board.

Editor,

Pharmacy and Poisons Board

UPCOMING EVENTS

- World Health Organization GBT Assessment



PHARMACY AND POISONS BOARD

pr@ppb.go.ke
info@ppb.go.ke



Pharmacy and Poisons Board



@ppbkenya

CONTENTS

- 5 Pharmacists Challenged to Lead Healthcare Transformation.**
- 6 Regulatory Reform Dialogue Takes Centre Stage at PSK Conference.**
- 6 Stronger Stakeholder Collaboration Key to Patient Safety.**
- 7 Stronger Medicines Regulation to Support Local Pharmaceutical Manufacturing.**
- 8 Kenya Advances Towards WHO Maturity Level 3 Status.**
- 8 95 Arrested as Crackdown on Illegal Pharmaceutical Outlets Intensifies.**
- 9 Kenya Launches Strategy to Accelerate Local HPT Manufacturing.**
- 10 Productivity Management Initiative Targets Improved Service Delivery.**
- 10 Strategic Partnership to Advance Regulatory Science and Innovation.**
- 11 Health Sector Leaders Align Priorities and Review Ebola Preparedness.**
- 12 Good Pharmacy Practice Survey Sets Stage for Regulatory and Policy Reforms.**
- 12 AfriSummit 2026 Preparations Advance.**
- 13 Counties Strengthen Pharmacovigilance and Maternal Immunisation Safety Surveillance.**
- 14 Kenya Deepens Vaccine Research and Regulatory Collaboration.**
- 14 Regulatory Reforms Strengthen Oversight of Health Products and Technologies.**
- 15 Regional Partners Strengthen Action Against Illicit Drug Trafficking.**
- 16 Public and Private Health Leaders Advance Collaboration on Healthcare Delivery.**
- 16 Kenya and India Discuss Pharmaceutical Regulation and Local Manufacturing.**
- 17 New Framework Strengthens Medical Device Software Regulation.**
- 17 Regulatory Systems Strengthened to Improve Access to Quality Medicines.**
- 18 Pictorial.**

Pharmacists Challenged to Lead Healthcare Transformation



Health Cabinet Secretary Hon. Aden Duale makes his remarks during the conference

The Chairperson of the Pharmacy and Poisons Board (PPB), Dr John M. Munyu, MBS, has challenged pharmacists to take a leading role in transforming healthcare through innovation, professionalism and ethical practice.

Speaking on 24 June 2026 at the 46th Pharmaceutical Society of Kenya (PSK) Annual Scientific Conference in Mombasa, which was graced by Cabinet Secretary for Health Hon. Aden Duale, Dr Munyu said pharmacists must move beyond participating in healthcare transformation and take the lead in advancing quality healthcare, research, manufacturing, regulation and public service.

Dr Munyu said the conference theme, "Pharmacists Leading Transformation and Innovation Towards the Highest Attainable



Pharmacy and Poisons Board Chairperson, Dr. John M. Munyu addresses participants at the 46th Pharmaceutical Society of Kenya Annual Scientific Conference

Standards of Health", reflected ongoing reforms at PPB aimed at strengthening regulation, enhancing public health protection and supporting the growth of the pharmaceutical sector.

He reaffirmed the Board's commitment to eliminating illegal pharmaceutical operations, warning that unlicensed medicine outlets, unqualified practitioners and wholesalers supplying medicines to illegal operators would face firm regulatory action, including prosecution, disciplinary measures and licence revocation.

The Chairperson highlighted key reforms undertaken by the Board, including increased human resource capacity, implementation

of the Health Products and Technologies Rules, strengthened Good Storage and Distribution Practice inspections, adoption of the Good Pharmacy Practice Guidelines, rollout of the Practice 360 compliance platform and the use of artificial intelligence and track-and-trace technologies to strengthen regulatory oversight.

Dr Munyu noted that the reforms had positioned Kenya on the path towards attaining World Health Organization Maturity Level 3 status, with formal benchmarking expected in September 2026. He said achieving Maturity Level 3 would strengthen confidence in Kenya's regulatory system, support local manufacturing and improve access to quality-assured medical products.

He called on pharmacists, professional associations and industry stakeholders to embrace compliance, innovation and self-regulation, emphasising that regulatory transformation requires collective action.

The conference was attended by Principal Secretary for Public Health and Professional Standards Ms Mary Muthoni, CBS, PPB Chief Executive Officer Dr Ahmed I. Mohamed and other health sector leaders.



Delegates follow proceedings during the 46th Pharmaceutical Society of Kenya Annual Scientific Conference



Health Cabinet Secretary Hon. Aden Duale, Public Health Principal Secretary, Ms. Mary Muthoni and Pharmacy and Poisons Board Chairperson, Dr. John Munyu among other delegates during the conference

Regulatory Reform Dialogue Takes Centre Stage at PSK Conference



Conference participants follow proceedings during the panel session

The 46th Pharmaceutical Society of Kenya Annual Scientific Conference provided a platform for dialogue on emerging regulatory developments shaping Kenya's pharmaceutical sector.

Speaking on 26 June 2026 during a breakout session on "Regulatory Developments in the Market in Kenya from a Regulatory Standpoint: Trends and Opportunities", Deputy

Director, Product Safety, Dr Christabel Khaemba highlighted the evolution of regulatory affairs from a function focused mainly on product registration to a strategic discipline overseeing the entire lifecycle of medical products.

Dr Khaemba noted that marketing authorisation is no longer the final step in regulation, with continuous monitoring of the safety and effectiveness of medicines through pharmacovigilance playing a central role in protecting patients and ensuring health products

continue to deliver their intended benefits.


She highlighted key regulatory milestones, including the adoption of risk-based regulatory approaches, application of regional and international reliance mechanisms, digitalisation of regulatory systems, strengthened oversight of local health products manufacturing and enhanced pharmacovigilance systems.

Dr Khaemba said the advances had improved regulatory efficiency and strengthened Kenya's readiness to regulate emerging health technologies.

She called for continued efforts to strengthen local pharmaceutical manufacturing, expand access to quality-assured medicines and position Kenya as a competitive regional regulatory hub as the Africa Medicines Agency becomes operational.



Pharmacy and Poisons Board Deputy Director, Product Safety, Dr. Christabel Khaemba makes her remarks during the Conference



Dr. Christabel Khaemba among the pannelist at the 46th Pharmaceutical Society of Kenya Scientific Conference

Stronger Stakeholder Collaboration Key to Patient Safety

The Pharmacy and Poisons Board has called for stronger collaboration with pharmaceutical sector stakeholders to advance patient safety, regulatory excellence and access to quality, safe and effective health products.

PPB convened a Regulator Engagement Forum on 26 June 2026 during the 46th Pharmaceutical Society of Kenya Annual Scientific Conference to discuss key regulatory priorities,



including pharmacy practice, product registration, post-market surveillance, pharmacovigilance and the Board's journey towards attaining World Health Organization Maturity Level 3 status.

Representing the Board of Directors, Dr Isha Anand underscored the importance of sustained collaboration between PPB and stakeholders in strengthening regulatory systems and safeguarding public health.



Pharmacy and Poisons Board, Medical Devices Lead, Dr. Paulyne Wairimu makes her remarks during the conference



Pharmacy and Poisons Board, Director of Pharmacy Practice, Dr. Wilfred Ochieng during the PPB session.

The panel featured Dr Wilfred Ochieng, Dr Paulyne Wairimu, Dr Edward Abwao, Dr Jonathan Mariakol and Dr Christabel Khaemba, who shared insights on strengthening Kenya's pharmaceutical regulatory landscape.



Pharmacy and Poisons Board, board member, Dr. Isha Anand addresses the conference participants



Pharmacy and Poisons Board team, led by Director of Pharmacy Practice Dr. Wilfred Ochieng pose for a group photo with the PSK President Dr. Wairimu Mbogo and Dr. Eva Amwai



Stronger Medicines Regulation to Support Local Pharmaceutical Manufacturing

Strengthening Kenya's medicines regulatory system remains central to the Pharmacy and Poisons Board's efforts to support local pharmaceutical manufacturing, attract investment and improve access to quality health products.

Speaking on 25 June 2026 during the Pharmacy Career Fair and Employer Engagement Forum at the 46th Pharmaceutical Society of Kenya Annual Scientific Conference, Senior Regulatory Officer Dr Abdulkadir Omar said PPB's pursuit of World Health Organization Maturity Level 3 status was expected to enhance the acceptance of Kenya's pharmaceutical products in



Dr. Abdulkadir Omar makes his remarks during the panel discussion

regional and international markets. He noted that attaining Maturity Level 3 would create a more

predictable and trusted regulatory environment, encourage investment in the pharmaceutical

sector, support industry growth and create employment opportunities. Dr Omar highlighted PPB's continued support for local manufacturers through regulatory guidance, capacity-building

initiatives and accelerated pathways for locally produced medicines and health products, in line with the Government's Buy Kenya, Build Kenya agenda.

The session highlighted the role of a

strong regulatory system in driving pharmaceutical sector growth, strengthening local production and expanding access to safe, quality and affordable healthcare.

Kenya Advances Towards WHO Maturity Level 3 Status



Pharmacy and Poisons Board Director of Pharmacy Practice, Dr. Wilfred Ochieng during the panel session

Kenya's regulatory system and support access to quality, safe and effective medical products.

He said the Maturity Level 3 framework is anchored on regulatory principles including consistency, independence, impartiality, clarity, proportionality and transparency.

Dr Ochieng noted that PPB was strengthening institutional capacity through investment in human resources, digital systems, operational efficiency and transparency to improve regulatory performance and service delivery.

The Pharmacy and Poisons Board has advanced efforts towards attaining World Health Organization Maturity Level 3 status, a globally recognised benchmark of a stable, well-functioning and integrated medicines regulatory system.

Speaking on 25 June 2026 during

a panel discussion on "Balancing Regulatory Maturity with Business Continuity, Investor Confidence and Market Access", Director of Pharmacy Practice Dr Wilfred Ochieng said attaining Maturity Level 3 would demonstrate the strength and predictability of



95 Arrested as Crackdown on Illegal Pharmaceutical Outlets Intensifies



Pharmacy and Poisons Board Drug Inspectors attend a briefing meeting at the Headquarters

The Pharmacy and Poisons Board intensified action against illegal

pharmaceutical operations, arresting 95 individuals and closing

48 unlicensed medicine outlets during a week-long surveillance exercise in Nairobi and Kajiado counties.

The operation, which ended on 19 June 2026, involved inspections of 155 pharmaceutical premises in Kibra, Korogocho, Eastleigh, Dandora, Mathare, Embakasi, Nairobi West and Rongai.

PPB Head of Good Distribution Practices and Enforcement Julius Kaluai said the inspections revealed widespread non-compliance



Pharmacy and Poisons Board Chief Executive Officer, Dr. Ahmed Mohamed chairs a briefing meeting before the crackdown

with pharmaceutical regulations, resulting in arrests and prosecutions.

"Out of the 155 premises inspected, 95 were found to be operating illegally and the individuals responsible were arrested. The suspects have since been presented before courts in Kajiado, Kibra and Makadara, and we are awaiting the outcome of the cases," said Kaluai.

The Board also ordered the closure of 48 premises operating without valid licences and engaged county governments, county security teams and the National Police Service to ensure the outlets remained closed.

PPB officers confiscated



Mr. Solomon Koech places a closure notice on an illegal chemist during the crackdown

approximately 169 cartons of medicines from the illegal outlets. The seized products are being held pending court directions on their disposal.

Kaluai warned that operating

pharmaceutical premises without the required licences violates the law and poses a risk to public health. He urged medicine providers to comply with regulatory requirements and called on the public to purchase medicines only from registered and licensed pharmacies and chemists.

"Licensed premises are required by law to display their licences prominently where clients can easily see them. Members of the public should always verify these licences before seeking services or purchasing medicines," he said.

PPB continues to strengthen surveillance, enforcement and public awareness to protect Kenyans from unsafe and unregulated pharmaceutical practices.



Mr. Symon Logisoi picks medicines from an illegal chemist

Kenya Launches Strategy to Accelerate Local HPT Manufacturing



Medical Services Principal Secretary, Dr. Ouma Oluga officially launches the strategy

Pharmacy and Poisons Board Chief Executive Officer Dr Ahmed

I. Mohamed participated in the launch of the Kenya Health

Products and Technologies Local Manufacturing Strategy 2026–2030 on 23 June 2026.

The launch was presided over by Principal Secretary for Medical Services Dr Ouma Oluga on behalf of Cabinet Secretary for Health Hon. Aden Duale.

The Strategy provides a roadmap for strengthening local production of health products and technologies, reducing reliance on imports, enhancing health security, promoting innovation and supporting sustainable access to quality and affordable health commodities.



*Pharmacy and Poisons Board
Chief Executive Officer, Dr. Ahmed
Mohamed during the launch*

The initiative is expected to accelerate the growth of Kenya's health products manufacturing industry, support Universal Health



Coverage and strengthen the manufacturing hub for health products and technologies.

Productivity Management Initiative Targets Improved Service Delivery



*National Productivity and Competitiveness Centre Chief Executive Officer,
Pro. Nahashon Moitaleel during the productivity workshop*

The Pharmacy and Poisons Board participated in a five-day Productivity Management Framework workshop from 15 to 20 June 2026 to consolidate its Productivity Baseline Index and strengthen productivity management systems.

Facilitated by experts from the National Productivity and

Competitiveness Centre, the workshop focused on integrating productivity measurement and management into the Board's planning, monitoring and implementation processes.

National Productivity and Competitiveness Centre Chief Executive Officer Prof. Nahashon Moitaleel emphasised the



importance of building a culture that recognises performance, promotes value creation and supports continuous improvement. The initiative supports PPB's efforts to enhance efficiency, accountability and service delivery in the execution of its public health mandate.

Strategic Partnership to Advance Regulatory Science and Innovation

The Pharmacy and Poisons Board and Strathmore University signed a Memorandum of Understanding

on 10 June 2026 to strengthen collaboration in regulatory science, research, innovation and capacity

building.

The MoU was signed by PPB Chief Executive Officer Dr Ahmed



Pharmacy and Poisons Board Chief Executive Officer, Dr. Ahmed Mohamed and the Strathmore Vice Chancellor Sign the MoU

I. Mohamed and Strathmore University Deputy Vice Chancellor for Research and Innovation Prof. Izael Da Silva.

The partnership will support joint research, regulatory science training, local pharmaceutical manufacturing, medication therapy management, innovation and knowledge management.




The collaboration aims to advance regulatory excellence, strengthen



Strathmore Deputy Vice Chancellor, Research and Innovation Prof. Izael Da Silva during a meeting at the Pharmacy and Poisons Board

compliance and translate research and innovation into practical solutions that improve healthcare regulation and access to quality, safe and effective health products and technologies.



Health Sector Leaders Align Priorities and Review Ebola Preparedness



Health Sector leaders join Public Health and Professional Standards PS Mary Muthoni for a group photo

Pharmacy and Poisons Board Chief Executive Officer Dr Ahmed I. Mohamed participated

in a high-level health sector management meeting chaired by Principal Secretary for Public



Pharmacy and Poisons Board Chief Executive Officer, Dr. Ahmed Mohamed, during the meeting

Health and Professional Standards Ms Mary Muthoni on 08 June, 2026. The meeting brought together

chief executive officers of Semi-Autonomous Government Agencies and heads of directorates, divisions and units to review progress, strengthen coordination

and align priorities for the 2026/27 Financial Year.

Health sector leaders also reviewed Kenya's preparedness for Ebola Virus Disease and other public

health emergencies, focusing on surveillance, laboratory capacity, risk communication and coordinated response mechanisms.

Good Pharmacy Practice Survey Sets Stage for Regulatory and Policy Reforms



Pharmacy and Poisons Board Director of Pharmacy Practice, Dr. Wilfred Ochieng makes his remarks during the validation of the survey report

The Pharmacy and Poisons Board and stakeholders validated the



Meeting participants follow proceedings

Good Pharmacy Practice Baseline Survey Report on 3rd June 2026.

The survey, conducted across 43 counties and more than 600 health facilities, assessed pharmacy workforce capacity, infrastructure, service delivery and compliance with Good Pharmacy Practice standards.

The findings will guide evidence-based regulatory and policy reforms, strengthen pharmacy workforce development, improve infrastructure and patient safety, and inform updates to Good Pharmacy Practice guidelines and professional standards.

The report will also support Kenya's efforts towards Universal Health Coverage and Sustainable Development Goal 3 on good health and well-being.

The next phase will involve the launch of the final report and implementation of county-specific action plans to address identified gaps and advance pharmacy practice nationwide.



AfriSummit 2026 Preparations Advance

The Pharmacy and Poisons Board participated in a stakeholder meeting on 2nd June, 2026 to advance preparations for the sixth edition of AfriSummit 2026.

Discussions focused on healthcare regulation, innovation, local manufacturing and access to quality health products across Africa.





Pharmacy and Poisons Board Head of Medical Devices Unit, Dr. Paulyne Wairimu makes her presentation during the breakfast meeting

Speaking on behalf of Acting Chief Executive Officer Dr Ahmed Mohamed, Head of the Medical Devices Unit Dr Paulyne Wairimu emphasised the role of



Afrisummit breakfast meeting attendees pose for a group photo

collaborative platforms in fostering partnerships and promoting regulatory harmonisation across the continent.

Dr Wairimu highlighted Kenya's growing role as a regional hub for health products and technologies and shared updates on PPB's institutional reforms and progress

towards attaining World Health Organization Maturity Level 3 status.

She also underscored the importance of local pharmaceutical manufacturing in strengthening health security and supporting economic growth.

Counties Strengthen Pharmacovigilance and Maternal Immunisation Safety Surveillance



Pharmacy and Poisons Board Deputy Director of Product Safety, Dr. Christabel Khaemba hands a recognition letter to a participant

The Pharmacy and Poisons Board convened a stakeholder meeting in Machakos on 29 May, 2026 to strengthen pharmacovigilance and maternal immunisation safety surveillance.

The meeting brought together County Pharmacovigilance Focal Persons and representatives from Kenyatta National Hospital and Moi Teaching and Referral Hospital.

Discussions focused on improving patient safety and strengthening monitoring and reporting systems to support maternal immunisation safety surveillance and implementation of pharmacovigilance activities at



Pharmacovigilance focal persons during the meeting



county level.



PPB reaffirmed its commitment

to working with County Pharmacovigilance Focal Persons to strengthen coordination and safeguard the quality, safety and efficacy of health products and technologies.


The Board also recognised Pharmacovigilance Focal Persons from Samburu, Kilifi, Nakuru, Meru, Siaya and Nyeri counties, as well as Kenyatta National Hospital, for improved reporting performance.



Kenya Deepens Vaccine Research and Regulatory Collaboration



President William Samoei Ruto pose for a photo with the International Vaccine Institute Director-General Jerome Kim at State house, Nairobi



The International Vaccine Institute Director-General Jerome Kim engages President William Samoei Ruto at State house, Nairobi

President William Samoei Ruto held talks with International Vaccine Institute Director-General Jerome Kim at State House, Nairobi, on 14 May, 2026 to strengthen Kenya's longstanding partnership with the Institute.

Discussions focused on continued collaboration in vaccine research and development, clinical trials, manufacturing partnerships, regulatory strengthening and staff development.

The International Vaccine Institute will also work with Kenyan academic, research and regulatory institutions, including the Kenya Medical Research Institute, Kenya Biovax Institute and the Pharmacy and Poisons Board.

The engagement followed Kenya's election to the vice-presidency of the International Vaccine Institute Global Council and representation on the Board of Trustees.

Regulatory Reforms Strengthen Oversight of Health Products and Technologies



The Chief of Staff and Head of Public Service Mr. Felix Koskei addresses participants during the conference



Public Health and Professional Standards PS, Mary Muthoni during the conference

The Pharmacy and Poisons Board highlighted key regulatory milestones at the 3rd Annual Regulatory Authorities and Agencies Conference held in Kitui on 7 May 2026.

PPB Chief Executive Officer Dr

Ahmed Mohamed presented on "Institutional Workplans Geared Towards Achieving Effective Regulatory Control", outlining reforms and interventions undertaken to strengthen oversight of health products and technologies.

Dr Mohamed highlighted enhanced regulatory surveillance to strengthen supply chain integrity, improved renewal processes for registered products and expanded detection and monitoring of risks through capacity building on adverse event reporting.



Pharmacy and Poisons Board Chief Executive Officer, Dr. Ahmed Mohamed makes his remarks during the 3rd Annual Regulatory Authorities and Agencies Conference

He also highlighted the decentralisation of regulatory functions through 10 regional offices and investment in information and communication technology systems and infrastructure to improve efficiency, productivity and service delivery.


The conference, hosted by Chief of Staff and Head of Public Service Mr Felix Koskei, brought together Principal Secretaries, Board Chairpersons, Chief Executive Officers, regulators and governance experts to discuss regulatory



effectiveness, accountability, integrity and public confidence.

Principal Secretary for Public Health and Professional Standards Ms Mary Muthoni and PPB Board Chairperson Dr John Munyu also attended.

Regional Partners Strengthen Action Against Illicit Drug Trafficking



A group photo of the workshop participants

The Pharmacy and Poisons Board, in collaboration with the International Narcotics Control Board, launched a three-day regional training workshop on 7 May 2026 to strengthen regulated supply chains and combat illicit drug trafficking.

The workshop, held under the Global Rapid Interdiction of Dangerous Substances programme, brought together government agencies, international organisations and enforcement partners to strengthen

cooperation, information sharing and the use of GRIDS tools.

Participants highlighted the growing threat posed by illicit trade and trafficking of health products and technologies and the need for stronger regional and international collaboration.

The workshop also reviewed achievements under Operation African Star 2, conducted in July 2025, during which agencies from Kenya and neighbouring countries strengthened coordination and



Pharmacy and Poisons Board Corporate Services Director, Dr. Anthony Toroitich makes his remarks during the three-day workshop

intercepted illicit products entering through courier and parcel delivery systems.

A key focus was the introduction and operationalisation of the GRIDS and IONICS platforms in Kenya to strengthen tracking, monitoring and verification across regulated supply chains.

Participants called for stronger partnerships among regulatory authorities, law enforcement agencies, international organisations and the private sector to enhance supply chain integrity and consumer safety.



Public and Private Health Leaders Advance Collaboration on Healthcare Delivery



Health Cabinet Secretary Hon. Aden Duale address health leaders during the meeting

Acting Pharmacy and Poisons Board Chief Executive Officer Dr Ahmed I. Mohamed participated in the Kenya Healthcare Federation

CEO Forum in Nairobi on 24 April 2026.

The forum, presided over by Cabinet Secretary for Health Hon. Aden Duale, brought together stakeholders from the public, private and faith-based health sectors to discuss structured collaboration in strengthening healthcare delivery.

The Cabinet Secretary highlighted the role of private and faith-based providers in advancing health sector reforms and underscored the



Pharmacy and Poisons Board Acting Chief Executive Officer, Dr. Ahmed Mohamed during the meeting

importance of accountability and compliance across the healthcare system.



Kenya and India Discuss Pharmaceutical Regulation and Local Manufacturing



The Indian High Commissioner to Kenya, Dr. Adarsh Swaika pose for a photo with the Pharmacy and Poisons Board Acting, Chief Executive Officer, Dr. Ahmed Mohamed

The High Commissioner of India to Kenya, Dr Adarsh Swaika, paid a courtesy visit to Pharmacy and Poisons Board Acting Chief Executive Officer Dr Ahmed Mohamed on 23 April 2026 to discuss regulation of health products and technologies in Kenya.

Discussions focused on ongoing regulatory reforms aimed at ensuring health products and technologies in the Kenyan market meet required standards of quality, safety and efficacy.


Dr Mohamed highlighted implementation of mandatory renewal of marketing authorisations to ensure only



Discussions during the meeting with the visiting Indian High Commissioner

compliant products remain on the market.

The meeting also discussed local pharmaceutical manufacturing, with PPB reaffirming its commitment to an enabling regulatory environment for locally manufactured products, including preferential fees and expedited



evaluation timelines of between three and six months.

The two leaders further discussed Good Manufacturing Practice inspections and their role in safeguarding public health and maintaining the integrity of the pharmaceutical supply chain.

The engagement reaffirmed collaboration between Kenya and India in advancing access to quality-assured, safe and effective health products.

New Framework Strengthens Medical Device Software Regulation



Software, including Software as a Medical Device and Software in a Medical Device.

The framework also provides guidance on artificial intelligence-powered medical devices in response to rapidly evolving technologies entering the Kenyan market.

The guidelines strengthen oversight of digital health technologies to ensure software used in diagnosis, treatment and monitoring meets required standards of safety, quality and performance in line with global best practice.

The Pharmacy and Poisons Board has developed guidelines to provide a framework for the regulation of Medical Device

Regulatory Systems Strengthened to Improve Access to Quality Medicines



Pharmacy and Poisons Board Acting Chief Executive Officer, Dr. Ahmed Mohamed chairs a meeting with the Gates Foundation delegates

Pharmacy and Poisons Board Acting Chief Executive Officer Dr Ahmed



Gates Foundation Lorraine Danks (Right) during the meeting

Mohamed held discussions with a Gates Foundation delegation led by Ms Lorraine Danks on 16 April 2026 to review collaboration in strengthening Kenya's medicines

regulatory system.

Dr Mohamed acknowledged the Foundation's support across key regulatory areas, including marketing authorisation,



post-market surveillance, quality control and information and communication technology

systems.

He highlighted support towards the final stages of the marketing authorisation process, backlog clearance and establishment of an enhanced reliance system, which have contributed to improving timely access to quality, safe and effective medicines.

The CEO also acknowledged the partnership's contribution to PPB's

progress towards attaining World Health Organization Maturity Level 3 status and strengthening Kenya's capacity to assure the safety, quality and efficacy of health products.

The engagement reaffirmed continued collaboration in building regulatory systems that support Universal Health Coverage and protect public health.



Pictorial...

6,784 Healthcare Interns Deployed to Strengthen Service Delivery



Pharmacy and Poisons Board Chairperson Dr John Munyu and Director of Pharmacy Practice Dr Wilfred Ochieng participated in the deployment of 6,784 healthcare interns under the 2026/27 Internship Programme on 29 June 2026.

The exercise, led by Cabinet Secretary for Health Hon. Aden Duale, reaffirmed the Government's commitment to strengthening Kenya's health workforce and improving healthcare service delivery.

Professional Examinations Assess Pharmacy Practice Competence



Pharmacists and pharmaceutical technologists from across the country undertook mandatory professional examinations administered by the Pharmacy and Poisons Board from 8 to 11 June 2026 across nine examination centres.

The examinations support PPB's mandate to ensure pharmacy professionals meet required standards of competence, ethics and professional practice before serving the public.

A competent pharmaceutical workforce is essential to ensuring access to quality, safe and effective medicines and supporting Universal Health Coverage.

Regulatory Reforms Showcased at 46th PSK Annual Scientific Conference




The Pharmacy and Poisons Board showcased its regulatory reforms and public health initiatives at the 46th Pharmaceutical Society of Kenya Annual Scientific Conference held from 24 to 26 June 2026.

Interactions at the PPB exhibition booth focused on ongoing regulatory initiatives, the Board's online platforms and stakeholder enquiries on access to quality, safe and effective health products and technologies.

The Board also engaged Presidential Advisor on Health Dr Daniel Mwai, PPB Board Members Dr Isha Anand and Ms Serah Kisilu, and other conference delegates and stakeholders.

Tree-Planting Initiative Supports Environmental Conservation



The Pharmacy and Poisons Board led a tree-planting exercise at Kinale Forest on 29 May 2026 as part of its commitment to environmental conservation and sustainability. The activity brought together PPB staff, stakeholders and community members in support of national forest restoration and environmental protection efforts.

Regulatory Services and Innovation Showcased at MEDEXPO 2026



The Pharmacy and Poisons Board participated in MEDEXPO 2026 at the Sarit Expo Centre from 22 to 24 April 2026, showcasing its regulatory services and initiatives to assure the safety, quality and efficacy of medical products in Kenya.

Held under the theme "Advancing Healthcare Access and Innovation in Africa", the expo brought together industry leaders, innovators and stakeholders to exchange knowledge and explore solutions for strengthening healthcare systems.

Registered medicines
undergo regular review to maintain

SAFETY & QUALITY



Ensuring Effective, Safe and High-Quality Medicines

X     @ppb_kenya



REPUBLIC OF KENYA

**MINISTRY OF HEALTH
PHARMACY AND POISONS BOARD****PUBLIC ALERT****FALSIFIED PHESGO (PERTUZUMAB/TRASTUZUMAB) 600MG/600MG IN 10ML, BATCH NUMBER C5290S20**

The Pharmacy and Poisons Board ("the Board") is mandated by Cap 244 of the Laws of Kenya to protect and promote public health by regulating the pharmacy profession and ensuring access to quality, safe, and effective health products and technologies ("HPTs").

In furtherance of this mandate, the Board undertakes post-marketing surveillance activities to monitor HPTs circulating in the market and to take appropriate regulatory actions in safeguarding public health.

During the course of these surveillance activities, the Board has identified a falsified batch of **Phesgo (Pertuzumab/Trastuzumab)**, Batch Number **C5290S20**, currently circulating in the Kenyan market. The falsified batch contains discrepancies compared to the genuine Phesgo as follows:

1. Batch Number C5290S20 does not correspond to any authentic Roche batch number.
2. The vial contains a white powder, whereas genuine Phesgo is a ready-to-use, clear to opalescent, colorless to slightly brownish liquid solution intended for subcutaneous administration. Phesgo is never supplied as a powder and does not require reconstitution.

The falsified batch may contain incorrect, insufficient, or harmful ingredients, and its quality, safety, and efficacy cannot be guaranteed. Use of this product poses a serious risk to patient safety and public health

PUBLIC ADVISORY

1. Procurement agencies, distributors, wholesalers and retailers, pharmacists, pharmaceutical technologists, all healthcare professionals and members of the public should **immediately stop the distribution and use of Phesgo (Pertuzumab/Trastuzumab), Batch Number C5290S20** and **report any encounter with this falsified batch** to the Pharmacy and Poisons Board.
2. All stakeholders within the supply chain to procure HPTs exclusively from licensed manufacturers, importers, distributors, and retailers. Procuring from unlicensed sources endangers patients and constitutes a violation of the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya.

The Board, together with relevant Government investigative agencies, will take firm action against any individual or entity involved in the distribution of this and any other falsified batches of HPTs.

HOW TO REPORT

Any suspected falsified or substandard medicine, should be reported through the following official channels:

- Online portal: <https://pv.pharmacyboardkenya.org/users/mpublic>
- USSD Code: *271#
- Mobile App: mPvERS (Android & iOS)
- Email: pv@ppb.go.ke | pms@ppb.go.ke
- Telephone: 0795743049

The Pharmacy and Poisons Board remains committed to protecting and safeguarding public health. Your cooperation is essential in ensuring the quality, safety and efficacy of Health Products and Technologies in Kenya.




Dr. Ahmed I. Mohamed

Ag. CHIEF EXECUTIVE OFFICER

25th May 2026

PRODUCT PHOTO





REPUBLIC OF KENYA

MINISTRY OF HEALTH PHARMACY AND POISONS BOARD

PRESS STATEMENT

CLARIFICATION REGARDING A DAILY NATION ARTICLE ON PARALLEL IMPORTED MEDICINAL PRODUCTS

1. The Pharmacy and Poisons Board (the "Board") has noted the article published in the **Daily Nation on 30 June 2026**, titled **"90% of Nairobi Pharmacies Found Selling Illegal Drugs,"** concerning the regulatory compliance of **selected parallel imported medicinal products** marketed in Nairobi County.
2. The headline creates the impression that the medicinal products assessed were illegal, substandard, falsified or unsafe for patient use. **This does not accurately reflect the findings of the study.**
3. The study was conducted between **September 2023 and October 2024** and therefore reflects the regulatory environment that existed during that period.
4. Parallel importation is a lawful mechanism provided for under the Pharmacy and Poisons (**Parallel Imported Medicinal Substances**) Rules, 2019 to enhance the availability and affordability of medicines in Kenya.
5. The medicinal products assessed in the study were approved under this regulatory framework, manufactured by the original manufacturers in compliance with internationally recognised Good Manufacturing Practice standards, and were **not** found to be substandard, falsified or unsafe for patient use.
6. Having substantially improved access to and affordability of medicines through the parallel importation framework, the Board subsequently introduced additional regulatory reforms.
7. Consequently, **no new applications for parallel imported medicinal products have been approved since October 2025.**
8. The Board remains committed to ensuring that only health products meeting the required standards of quality, safety and efficacy are available in Kenya.
9. The Board encourages the public, the media and all stakeholders to seek accurate regulatory information from the Pharmacy and Poisons Board and to verify regulatory matters before publication in order to promote responsible reporting.

Dr. Ahmed I. Mohamed
CHIEF EXECUTIVE OFFICER

04 JULY 2026



PHARMACY AND POISONS BOARD

STOP ANTIMICROBIAL RESISTANCE!

You can help prevent AMR by:



- ✓ Using antibiotics only when prescribed
- ✓ Completing your full treatment
- ✓ Never sharing or using leftover antibiotics
- ✓ Practicing good hygiene & vaccination to prevent infections
- ✓ Avoiding self-medication & over-the-counter antimicrobials
- ✓ Disposing of antimicrobials safely

**YOUR ACTIONS TODAY PROTECT
FUTURE GENERATIONS!**